About CanniOasis
CanniOasis is a Healthcare company based in Singapore (Singapore) founded in 2021 by David Jacob, and was acquired by Compass Ventures Group in October 2024. Precision cannabinoid-based drugs are developed for neurological disorders. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery.
Company details
CanniOasis was founded in 2021 in Singapore. Precision cannabinoid-based drugs for neurological disorders are developed through an AI-based theragnostic platform. MicroRNA and epigenetics are utilized to build proprietary drug screening platforms for cannabinoid treatments. Operations are centered in the biotechnology sector, with a focus on neurological diseases. The company is led by co-founder David Jacob, and activities are based in Singapore.
- Headquarters Singapore, Singapore
- Founders David Jacob
- Stage Acquired
- SectorsHealthcare
- Website cannioasis.com
- Social LinkedIn
- Acquired by Compass Ventures Group (Oct 2024)
- Investors
- Acquired byCompass Ventures Group
(Oct 2024)
Investors in CanniOasis
CanniOasis has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Compass Ventures Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Compass Ventures Group is engaged in technology and innovation services. | compassvgg.com |
Investor details for CanniOasis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of CanniOasis
1 people are tracked at CanniOasis (1 in leadership).
| Name | Role | Group |
|---|---|---|
David Jacob | Co-Founder | Leadership |
Complete people profiles for CanniOasis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of CanniOasis
2 dated milestones of CanniOasis across 3 years, from founding to its latest funding, stage changes and deals.
- Founded CanniOasis is founded.
- Exit Acquired by Compass Ventures Group.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about CanniOasis
CanniOasis was founded in 2021.
CanniOasis is headquartered in Singapore, Singapore.
CanniOasis was founded in 2021 in Singapore. Precision cannabinoid-based drugs for neurological disorders are developed through an AI-based theragnostic platform. MicroRNA and epigenetics are utilized to build proprietary drug screening platforms for cannabinoid treatments. Operations are centered in the biotechnology sector, with a focus on neurological diseases. The company is led by co-founder David Jacob, and activities are based in Singapore.
CanniOasis has 1 investor. Key investors include Compass Ventures Group.
Yes. CanniOasis was acquired by Compass Ventures Group in October 2024.